Table 2.

Analysis of progression of oesophageal pre-neoplastic lesions in function of time

Patient #	Initial diagnosis	HER-2 amplification(FISH)/ overexpression (IHC)	Progression (yes/no)	Final diagnosis	HER-2 amplification(FISH)/ overexpression (IHC)	TTP or max follow-up time (months)	Status at follow-up
1	BO	NA / 0	Yes	LGD	A / 3+	120	Alive
2	LGD	A / 3+	Yes	ADC	A / 3+	12	Alive
3	LGD	A / 3+	Yes	HGD	A / 3+	24	Alive
4	LGD	A / 3+	Yes	ADC	A / 3+	24	Alive
5	LGD	A / 3+	Yes	ADC	A / 3+	120	Alive
6	BO	NA / 0	Yes	ADC	NA / 1+	48	Alive
7	LGD	A / 3+	Yes	ADC	A / 3+	12	Alive
8	LGD	A / 3+	Yes	HGD	A / 3+	24	Alive
9	BO	NA / 1+	Yes	ADC	NA / 1+	60	Alive
10	LGD	NA / 1+	Yes	HGD	NA / 1+	24	Alive
11	BO	NA / 1+	Yes	LGD	NA / 1+	36	Alive
12	BO	NA / 1+	No	BO	NA / 1+	48	Alive
13	BO	NA / 1+	No	BO	NA / 1+	96	Alive
14	HGD	A / 3+	No	HGD	A / 3+	12	Alive
15	BO	NA / 0	No	BO	NA / 0	36	Alive
16	BO	NA / 1+	No	BO	NA / 1+	36	Alive
17	BO	NA / 1+	No	BO	NA / 1+	24	Alive
18	BO	NA / 0	No	BO	NA / 0	60	Alive
19	BO	NA / 2+	No	LGD	NA / 2+	72	Alive
20	BO	NA / 1+	No	BO	NA / 1+	48	Alive
21	BO	NA / 0	No	BO	NA / 0	72	Alive

Abbreviations: BO, Barrett’s oesophagus

LGD, low-grade dysplasia

HGD, high-grade dysplasia

ADC, adenocarcinoma

FISH, fluorescence in situ hybridization

IHC, immunohistochemistry

TTP, time to progression (calculated for those patients who progressed)

maximum follow-up time (calculated for non-progressors patients).